Thus, we propose a new regulatory mechanism for RRM2 transcription by the S-phase MYBL2 complex in CRC cells and a novel potential synergistically therapeutic strategy by simultaneously inhibiting transcription and promoting degradation of RRM2 for CRC treatment. Here, RRM2 is linked to colorectal carcinoma.